Tenders of Aok Niedersachsen Die Gesundheitskasse

Germany-hanover: Beta-blocking Agents

Conclusion Of A Non-exclusive Discount Agreement According To § 130a Para. 8 Sgb V On Medicinal Products With The Active Ingredient Follitropin Alfa (atc Code: G03ga05).

Conclusion Of A Non-exclusive Discount Agreement According To § 130a Para. 8 Sgb V On Medicinal Products With The Active Ingredient Fampridine (atc Code: N07xx07).

The Aok Lower Saxony. The health insurance company For intends To enter into force Of exclusive contracts According to a public tender According to the regulations of the 4th part of the Gwb, Non-Exclusive medicinal discount contracts To the active substance Capsaicin (atc-code: N01bx04) With possible to complete all market participants (pharmaceutical entrepreneurs or communities pharmaceutical entrepreneurs) In the so-called “open-house model”. Aok Niedersachsen will not make a selection decision and any interested pharmaceutical company will submit an Identian contract offer. In the open-house model Gelten For All participants Uniform conditions. Contract contents, conditions and access procedures are uniform – Individual negotiations are not carried out in principle. The contract term Amounts Maximum twenty-four months, The earliest start of the contract is 01.08.2022. All contracts Ends Late Ends On 31.07.2024, Independent From the date of each contract conclusion. Joined Bzw. A conclusion can be achieved within the twenty-four-month period in each case for the first one month. There is a right to terminate each six weeks at the end of the month. The Aok Lower Saxony Behaves Pre, Already During the contract term The non-exclusive open-house discount contracts Replace by exclusive discount contracts. With the entry into force Described, Exclusive Discount Contracts Become the Open-house Contracts According to The Contractual Regulation Finished, D. H. The Open-house Contract Ends Automatically. The Aok Lower Saxony Experiences Exclusive Discount Contracts As a rule Six to eight months After the publication The corresponding notice of invitation to tender In the Supplement to the Official Journal The European Union In force. The Future Contract Partners In the Open-house Model Become Prayer, Regarding This Notice of Call Regular In the Supplement to the Official Journal of the European Union To Inform. Interested pharmaceutical companies can request the contract documents as well as the contract terms under The I.1) Contracts To the active ingredient Capsaicin (atc-code: N01bx04) Become concluded for the first time with effect on 01.08.2022. Interested parties, The To This Date Contractors Want to, Have The Contract Documents to be submitted by 30.06.2022 At the address mentioned in the Contract Documents. It Comes To Access At The Aok Lower Saxony. Later contract closures are During the twenty-four-month maximum duration ever. The Aok Necessary To The Required Works, e.g., The Contract Message In The Lauer-taxe® Ensure Skills. The exact periods of entry are announced with the contract documents. In the case of the above publication, Es sich Not Um The award of a public contract within the meaning of the Directive (2014/24/eu) Gwb. In order to guarantee a farthest degree of transparency For the intended conclusion of the contract, the publication In the Supplement to the Official Journal of the European Union succeeds. In the absence of a corresponding publication form, the order notice is used. The term specifications resulting therefrom, such as e.g. The term “open procedure” is the only use of this publication form and the publication platform is due. A further meaning, In particular, a subjugation of subcontracting regulations, To the extent that you are not obligatory for legal reasons, Is that not related.. The Procurement Is Related To A Project And/or Programme Financed By European Union Funds: No

Germany-hanover: Muscle Relaxants

Germany-hanover: Antibacterials For Systemic Use

Germany-hanover: Pharmaceutical Products

Conclusion Of A Non-exclusive Discount Agreement According To § 130a Para. 8 Sgb V For Medicinal Products With The Active Ingredient Combination Of Vilanterol And Fluticasone Furoate (atc Code: R03a

Germany-hanover: Pharmaceutical Products

Germany-hanover: Medicinal Products Used In Diabetes